Terveystalo - For a healthier life

Stocks
841

Screenshot_20251223_085134_Chrome

M&A heating up!

:money_mouth_face:

18 Likes
842

Here is the full release. :backhand_index_pointing_down:

And here are the analyst’s comments. :backhand_index_pointing_down:

16 Likes
843

Here are Roni’s comments regarding how upper respiratory tract infection diagnoses are at a lower level than the comparison period.

According to Terveystalo’s open reporting data, the upper respiratory tract infection diagnoses made by the company have been at a significantly lower level in the latter part of the year compared to the corresponding period last year, although the decrease is partly explained, in our assessment, by the company’s shrunken occupational health customer base. For both Terveystalo and Pihlajalinna, the “flu season” is one of the earnings drivers in Q4 and Q1, but in our view, its significance for the long-term development of the investment cases should not be overemphasized. In our assessment, achieving the guidance for the current year requires a strong end to the year from both, and the development of the flu season may become a decisive factor in terms of reaching the guidance.

3 Likes
844

Screenshot_20260107_132441_Chrome

Something like this in Arvopaperi magazine today :mechanical_arm::money_mouth_face:

21 Likes
845

If you can’t access Arvopaperi, here is the press release:

The companies’ combined revenue in 2024 was approximately EUR 8.2 million and Terveystalo’s corresponding revenue was approximately EUR 1.3 billion, so it is likely safe to say that this won’t require any major measures. However, the release states the following:

“The acquisition supports Terveystalo’s strategy to grow in specialized medical care and strengthens its position in the ophthalmic surgery market. Through the acquisition, Terveystalo gains access to new expertise, a wider network of clinics, and modern surgical technology, enabling a higher volume of cataract, lens, and refractive surgeries than before.”

33 Likes
846

PieksÀmÀen Lehti reports that retinal screenings for diabetic patients in the South Savo wellbeing services county will be transferred to Terveystalo. The article is behind a paywall, so the specific details remain unclear to me.

16 Likes
847

In Kauppalehti today, Jan 30, 2026

DNB Carnegie upgraded Terveystalo’s stock recommendation to buy, previously hold. The target price was raised to 11.30 euros from 10.10 euros.

21 Likes
848

Here are Roni’s pre-result comments as Terveystalo reports its results on Friday, February 13, 2026 :slight_smile:

At the end of the year, there was a risk of a profit warning hanging over the company, but as none has been issued, we have raised our forecast—which previously anticipated a slight profit warning—to the level required by the guidance. We expect revenue to have remained in decline at the end of the year, particularly due to challenges in the occupational health business and expiring outsourcing contracts. However, the guidance indicates a fairly clear improvement in profit, although it is worth noting that the comparison period was weighed down by one-off (non-adjusted) personnel expenses and a higher-than-normal depreciation load. In the report, we will focus particularly on the 2026 guidance, which we expect to indicate slowing earnings growth, as well as the outlook for the occupational health market and the publicly funded market, among other things. Comments regarding the recent Hohde Group acquisition are also of interest.

8 Likes